A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies (Q21245492)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies |
scientific article |
Statements
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies (English)
0 references
John J Nemunaitis
1 reference
Karen A Small
1 reference
Paul Kirschmeier
1 reference
Da Zhang
1 reference
Yali Zhu
1 reference
Ying-Ming Jou
1 reference
Paul Statkevich
1 reference
Siu-Long Yao
1 reference
Rajat Bannerji
1 reference
2013
0 references
11
0 references
259
0 references
1
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference